|
Delayed
Nasdaq
19:58:50 16/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.620 USD | -1.87% |
|
-25.36% | +84.51% |
| 10-15 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 08-20 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 36.08M | - | - | - | - | - |
| 68.98B | |||||
| 53.15B | |||||
| 50.83B | |||||
| 44.61B | |||||
| 40.57B | - | - | - | - | - |
- Stock Market
- Stocks
- EDSA Stock
- Charts Edesa Biotech, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
